Nucleoside analogues in 2008

Journal of HIV Therapy

Volumn 13, Issue 1, 2008, Pages 3-8

  Warwick, Zoe ^a   Churchill, Duncan ^a  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TENOFOVIR PLUS LAMIVUDINE PLUS NEVIRAPINE; UNCLASSIFIED DRUG; VIDEX EC; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEPHROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; SIDE EFFECT;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 52149087176     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med, 1987, 317, 185-191.
2. Hammer SM, Katzenstein DA, Hughes MD et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med, 1996, 335, 1081-1090.
3. DELTA: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. DELTA Coordinating Committee. Lancet, 1996, 348, 283-291.
4. Montaner JS, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. (Italy, the Netherlands, Canada and Australia study). JAMA, 1998, 279, 930-937.
5. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med, 1999, 341, 1865-1873.
6. van Leth F, Phanuphak P, Ruxrungtham K et al.; and the 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet, 2004, 363, 1253-1263.
7. Hirsch M, Steigbigel R, Staszewski S et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis, 1999, 180, 659-665.
8. Walmsley S, Bernstein B, King M et al.; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med, 2002, 346, 2039-2046.
9. Delfraissy JF, Flandre P, Delaugerre C et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naïve HIV-infected patients. AIDS, 2008, 22, 385-393.
10. Riddler SA, Haubrich R, DiRienzo G et al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. XVIth International AIDS Conference, Toronto, August 2006. Abstract ThLB0204.
11. Churchill DR, Pym AS, Galpin S et al. The Rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Res Hum Retroviruses, 1991, 15, 1181-1189.
12. Nieuwkerk PT, Gisolf EH, Colebunders R et al. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS, 2000, 14, 181-187.
13. Duvivier C. Lower rate of virological suppression in naïve patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen: results from the Hippocampe-ANRS 121 trial. 10th European AIDS Conference, Dublin, November 2005. Abstract PS1/3.
14. Tebas P, Zhang J, Yarasheski K et al.; for the AIDS Clinical Trials Group (ACTG). Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS Clinical Trial Group 5125S). J Acquir Immune Defic Syndr, 2007, 45, 193-200.
15. Squires K, Johnson V, Katlama C et al. The ATLANTIC study: a randomised open label trial, comparing two protease inhibitor sparing antiretroviral strategies versus standard PI-containing regimens, final 48 week data. XIIIth International AIDS Conference, Durban, July 2000. Abstract LbPeB 7046.
16. Gulick RM, Ribaudo HJ, Shikuma CM et al. AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med, 2004, 350, 1850-1861.
17. Staszewski S, Keiser P, Montaner J et al. Abacavir, lamivudine, zidovudine in antiretroviral naïve HIV-infected adults. JAMA, 2001, 285, 1155-1163.
18. Gallant JE, Rodriguez AE, Weinberg W et al. Early non-response to tenofovir (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2003, Abstract H-1722a.
19. Jemsek J, Hutcherson P, Harper E. Poor virological responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004. Abstract 51.
20. Moyle G, Higgs C, Teague A et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a two-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther, 2006, 11, 73-78.
21. d'Ettorre G, Zaffiri L, Ceccarelli G et al. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. HIV Clin Trials, 2007, 8, 182-188.
22. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med, 2008, 9, in press.
23. Clumeck N, Pozniak A, Raffi F and the EACS Executive committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med, 2008, 9, 65-71.
24. Podzamczer D, Ferrer E, Sanchez P et al. A randomized comparison of abacavir and stavudine, combined with lamivudine/efavirenz, in antiretroviral-naïve patients. Final 96-week results (ABCDE study). 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005. Abstract 587.
25. Gallant JE, Staszewski S, Pozniak A et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients. A 3-year randomized trial. JAMA, 2004, 292, 191-201.
26. Maitland D, Moyle G, Hand J et al. Early virological failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS, 2005, 19, 1183-1188.
27. Kearney BP, Sayre JR, Flaherty JF et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol, 2005, 45, 1360-1367.
28. Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naïve patients. A randomized trial. JAMA, 2004, 292, 180-190.
29. Carr A, Amin J. Reasons for treatment success with initial ART: an analysis of 22,635 participants in 64 randomized, controlled trials and 14 prospective cohorts. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 782.
30. Servoss JC, Kitch DW, Andersen JW et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS clinical trial group (1989-1999). J Acquir Immune Defic Syndr, 2006, 43, 320-323.
31. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, efavirenz for HIV. N Engl J Med, 2006, 354, 251-260.
32. Eron J, Yeni P, Gathe J et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet, 2006, 368, 476-482.
33. DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. Clin Infect Dis, 2004, 39, 1038-1046.
34. Moyle G, DeJesus E, Cahn P et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr, 2005, 38, 417-425.
35. Madruga J, Cassetti I, Suleiman JM et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: 3-year follow-up after switching therapy. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2007. Abstract H-364.
36. Martin A Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS, 2004, 18, 1029-1036.
37. Moyle GJ, Sabin C, Cartledge J, Reilly G. Lipid changes in a randomised, 48-weeks, open label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy: the RAVE study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 2005. Abstract H-340.
38. Sosa N, Hill-Zabala C, DeJesus E et al. Abacavir and lamivudine fixed dose combination once daily compared with abacavir and lamivudine twice daily in HIV infected patients over 48 weeks. J Acquir Immune Defic Syndr, 2005, 40, 422-427.
39. Smith KY, Fine D, Patel P et al. Efficacy and safety of abacavir/ lamivudine combined to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008, Abstract 774.
40. NIAID Modifies HIV Antiretroviral Treatment Study Combination Therapy that Includes ABC/3TC. (ACTG 5202) Press Release. February 28, 2008.
41. Rey D, Schmitt MP, Hoizey G et al. Early virologic non-response to once daily combination of lamivudine, tenofovir and nevirapine in antiretroviral naïve HIV-infected patients: preliminary results of the DAUFIN study. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 503.
42. Towner W, Kerrigan H, LaRiviere M et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naïve HIV infected patients: a pilot study. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004. Abstract P49.
43. Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy is not observed more frequently: a cohort and case-controlled study. J Acquir Immune Defic Syndr, 2004, 37, 1489-1495.
44. Nelson M, Cooper D, Schooley R et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006. Abstract 781.
45. Moreno S, Domingo P, Palacios R et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicentre study. J Acquir Immune Defic Syndr, 2006, 42, 384-385.
46. Gallant JE, Parish MA, Keruly JC et al. changes in renal function associated with tenofovir disoproxil fumarate, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005, 40, 1194-1198.
47. Winston A, Amin J, Mallon P et al. Minor changes in calculated creatinine clearance and anion gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med, 2006, 7, 105-111.
48. Moore R, Keruly J, Gallant J et al. Tenofovir and renal dysfunction in clinical practice. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 832.
49. Fux C, Simcock M, Wolbers M et al. Tenofovir treatment is associated with a decrease in calculated glomerular filtration rates in a large observational cohort. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles Ca, February 2007. Abstract 834.
50. Goicoechea M, Liu S, Best B et al. Increased renal impairment in patients receiving TDF+PI vs. TDF+NNRTI. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 835.
51. Wai H, Katsivas T, Ballard C et al. Risk factors for tenofovir-associated nephrotoxicity identified in an HIV clinic cohort. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 833.
52. Medicines Compendium 2008 Specific Product Characteristics: Viread, Gilead.
53. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reaction in the Western Australian HIV cohort study. Clin Infect Dis, 2006, 43, 99-102.
54. Reeves I, Churchill D, Fisher M. Clinical Utility of HLA-B57*01 testing in a UK clinic cohort. HIV Med, 2006, 7 (Suppl 1), O19.
55. Saag M, Balu R, Phillips E et al. High sensitivity of human leukocyte antigen-B*5701 as a marker of immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis, 2008, 46, 1111-1118.
56. Zucman D, Truchis P, Majerholc C et al. Prospective screening for human leukocyte antigen B57*01 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr, 2007, 45, 1-3.
57. DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 2008, 371, 1417-1426.
58. Stein JH, Currier JS. Risk of myocardial infarction and nucleoside analogues. Lancet, 2008, 371, 1391-1392.
59. Bani-Sadr F, Denoeud L, Morand P; Agence Nationale pour la Recherche contre le SIDA et les Hépatites Virales HC02-Ribavic Study Team. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr, 2007, 45, 123-125.
60. Brook MG, Gilson R, Wilkins E; BHIVA Hepatitis Coinfection Guidelines Committee. British HIV Association guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). HIV Med, 2005, 6 (Suppl 2), 84-95.
61. Johnson JA, Li J-F, Wei X et al. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naïve HIV-1-infected persons. XV International HIV Drug Resistance Workshop, July 2006, Sitges. Abstract 46.
62. Toro, Hicks C, the RESIST-1 Team. RESIST-1: a phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/c (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, November 2004. Abstract H-1137a.
63. Cahn P, the RESIST 2 Team. 24 week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir or an optimized ritonavir-boosted standard of care comparator PI in a large randomized multicenter trial in treatment-experienced HIV + patients. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004. Abstract PL14.3.
64. Katlama C. Carvalho MI, Cooper D et al. TMC 114/r outperforms investigator selected PI(s) in three class-experienced patients: week 24 primary analysis of POWER 1 (TMC 114-C213). 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005. Abstract WeOaLB0102.
65. Costagliola D, Descamps D, Assoumou L et al, and the ANRS AC11 Resistance study group. Prevalence of resistance to at least one drug in treated HIV infected patients with viral load >1000 copies/mL in 2004: a French nationwide study. 4th European HIV Drug Resistance Workshop, Monte Carlo, March 2006. Abstract 6.
66. Health Protection Agency. HIV Drug Resistance in the United Kingdom: data to end of 2004. CDR Weekly, 2006, 16(4), 26 January.
67. Johnson MA, Gathe JC Jr, Podzamczer D et al. A once-daily lopinavir/ritonavir-based regimen provides non-inferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr, 2006, 43, 153-160.
68. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005, 192, 1537-1544.
69. Campbell TB, Shulman NS, Johnson SC et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis, 2005, 41, 236-242.
70. Masquelier B, Tamalet C, Montes B et al.; ANRS AC11 Resistance study group. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther, 2004, 9, 315-323.
71. Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev, 2008, 10, 4-14.